Figure S5 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

Martina S.J. McDermott; Neil A. O’Brien; Benjamin Hoffstrom; Ke Wei Gong; Ming Lu; Jun Zhang; Tong Luo; Min Liang; Weiping Jia; Jenny J. Hong; Kevin Chau; Simon Davenport; Bin Xie; Michael F. Press; Richard Panayiotou; Abram Handly‐Santana; Joan S. Brugge; Leonard Presta; John A. Glaspy; Dennis J. Slamon

doi:10.1158/1078-0432.27030352.v1

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Supplemental Figure S5: Induction of apoptosis following 48 hr treatment of CLDN6 positive OVCA429 and CLDN6 negative M202 cells with a range of concentrations (50 μg/ml - 0.3658μg/ml) of CLDN6-23-ADC compared to control IgG ADC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

McDermott et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522ca0 https://doi.org/10.1158/1078-0432.27030352.v1

View at Publisher

Ask AI

Bookmark

Share

Figure S5 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

Ask about this paper

Abstract

Discussion

Cite This Study

Figure S5 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading